BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


SEARCH JOBS




 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 





Collaborations

Gilead Sciences, Inc. 

PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys, Inc.  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co., Inc.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead Sciences, Inc. (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead Sciences, Inc. (Seattle, WA) 





 Company News
Bristol-Myers Squibb Company (BMY) Submits New Drug Application To FDA For A Fixed-Dose Combination Tablet Of Atazanavir Sulfate With Cobicistat For People Living With HIV-1 4/14/2014 9:36:33 AM    More...
Bristol-Myers Squibb Company (BMY) Submits NDAs For Daclatasvir And Asunaprevir To The FDA For Hepatitis C Drugs 4/7/2014 6:50:56 AM    More...
Bristol-Myers Squibb Company (BMY) To Present Data For Daclatasvir In Multiple Investigational All-Oral Combinations Across Hepatitis C Genotypes At The International Liver Congress™ 3/24/2014 8:25:18 AM    More...
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/17/2014 6:54:22 AM    More...
Bristol-Myers Squibb Company (BMY)/Pfizer Inc. (PFE) Release: FDA Approves Eliquis® (Apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 3/14/2014 1:13:59 PM    More...
Bristol-Myers Squibb Company (BMY) Announces Dividend 3/4/2014 8:57:28 AM    More...
Bristol-Myers Squibb Company (BMY) Announces Charitable Donation Of $1 Million To Support Immuno-Oncology Education For Patients And Caregivers 3/3/2014 8:20:47 AM    More...
Clinical Trials Initiated For A New Molecule Jointly Identified By IRIC And Bristol-Myers Squibb Company (BMY) 2/26/2014 9:35:18 AM    More...
FDA Approves Bristol-Myers Squibb Company (BMY)' Drug For Rare Fat Disorder 2/25/2014 7:22:51 AM    More...
Bristol-Myers Squibb Company (BMY) And Pfizer Inc. (PFE) Release: In a Subanalysis, Eliquis® (apixaban) Reduced The Risk of Stroke And Demonstrated Fewer Major Bleeding Events Versus Warfarin Consistently Across Age Groups, Including Older Patients With Nonvalvular Atrial Fibrillation 2/21/2014 9:13:43 AM    More...
12345678910...